<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To assess whether a tolerance-induction regimen could be applied for unrelated (MUD) HCT in SAA, we retrospectively reviewed our HCT experience using unmanipulated 10/10 HLA-matched bone marrow grafts from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e> vs. MUD donors </plain></SENT>
<SENT sid="1" pm="."><plain>Conditioning was <z:chebi fb="3" ids="3498">CTX</z:chebi> 200 mg/kg (<z:chebi fb="3" ids="3498">CTX</z:chebi>) + rabbit ATG 10 mg/kg (ATG) for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e> (n = 9) and TLI (800 cGy) + <z:chebi fb="3" ids="3498">CTX</z:chebi>/ATG for MUD HCT ( n = 5) </plain></SENT>
<SENT sid="2" pm="."><plain>Immunoprophylaxis was CSA and short-course MTX </plain></SENT>
<SENT sid="3" pm="."><plain>Median patient age was 14.7 yr, median time to HCT 1.5 yr, and median follow-up 3 yr </plain></SENT>
<SENT sid="4" pm="."><plain>Outcome measures included EFS, time to engraftment, and cumulative incidence of GVHD (CIN of GVHD) for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e> and MUD cohorts </plain></SENT>
<SENT sid="5" pm="."><plain>EFS and stable engraftment rate were 100% </plain></SENT>
<SENT sid="6" pm="."><plain>CIN of <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD was: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e>, Grade I-II: 1 (11%), Grade III-IV: 0%; MUD, Grade I-II: 1 (20%), Grade III-IV: 1 (20%) </plain></SENT>
<SENT sid="7" pm="."><plain>CIN of <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD was: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e>, limited: 1 (11%), extensive: 0%; MUD, limited: 0%, extensive: 0% </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> immunosuppressive-compliant patients successfully weaned immunosuppression </plain></SENT>
<SENT sid="9" pm="."><plain>Although in limited patients, our results suggest that immunomodulatory TLI added to backbone <z:chebi fb="3" ids="3498">CTX</z:chebi>/ATG conditioning is a promising option for MUD HCT in SAA patients, which we will examine in a prospective clinical trial </plain></SENT>
</text></document>